The company said GAAP revenue for Q4 2023 was $696 million, down from $741 million a year earlier. GAAP operating income from continuing operations was $77 million, a margin of 11.1%. Adjusted operating income was $192 million, and the adjusted operating margin was 27.5%.

1. 01

   The company said GAAP revenue for Q4 2023 was $696 million, down from $741 million a year earlier. GAAP operating income from continuing operations was $77 million, a margin of 11.1%. Adjusted operating income was $192 million, and the adjusted operating margin was 27.5%.

2. 02

   The company said full-year 2023 GAAP revenue was $2,751 million, down from $3,312 million in 2022, and that GAAP EPS was $5.55 (versus $4.50 in 2022), while adjusted EPS from continuing operations was $4.65 (versus $6.92 in 2022).

3. 03

   The company said Diagnostics segment revenue for full-year 2023 was $1,459 million, down 28% on a reported basis from $2,020 million in 2022, and that adjusted operating profit margin was 22.0% (versus 38.7% in 2022). Life Sciences full-year revenue was $1,292 million, with no change on a reported basis.

4. 04

   The company said it expects full-year 2024 total revenue of $2.79 to $2.85 billion and adjusted EPS of $4.55 to $4.75. The company explained that this outlook is provided on a non-GAAP basis.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.